Vertex Pharmaceuticals Inc (VRTX.O): 2Q26 Consensus as of TODAY

First-page research excerpt

Flash |

31 Jul 2026 09:38:50 ET │ 10 pages

Vertex Pharmaceuticals Inc (VRTX.O)

2Q26 Consensus as of TODAY

CITI'S TAKE

Buy

Price (30 Jul 26 16:00)

US$481.70

Target price

US$585.00

Expected share price return

21.4%

Expected dividend yield

0.0%

Expected total return

21.4%

Market Cap

US$122,258M

Ahead of Vertex's 2Q26 readout Monday, we highlight our estimates

compared to Visible Alpha consensus including revenue ($3.2B both) and

non-GAAP EPS ($4.72 both). After the recent Crinetics acquisition

announcement (3Q closing expected) we expect interest around the

endocrinology pillar joining the portfolio and dynamics around new

product launches. That said, we still expect interest in the foundational CF

business, including Trikafta ($2.4B v $2.5B) and Alyftrek ($510M v $521M)

and the anticipated approval and launch of povetacicept in IgAN. We

outline our top estimates compared to recent VA consensus below.

Maintain Buy, $585 TP . Vertex is hosting a call Monday August 3rd at

4:30 PM ET.

Geoff Meacham, Ph.D.AC

Key questions expected during 2Q26 call

We anticipate the main topics of the call to be on 1) the strategy and development

plan of the announced Crinetics acquisition 2) the anticipated launch of

povetacicept in IgAN (11/30 PDUFA) and 3) new product launches including Alyftrek,

Casgevy and Journavx. We expect questions to revolve around the commercial

strategy of the broadening portfolio, launch metrics in both CF and pain and early

stage pipeline progress.

Mary Kate Davis

Jarwei Fang

Nishant Gandhi, Ph.D.

Figure 1. 2Q26 Citi v Consensus

© 2026 Citigroup Inc. No redistribution without Citigroup's written permission.

Source: Citi Research, Visible Alpha